Sign | PharmaShots

Bristol Myer Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019

GRYT Health and BMS Sign an Agreement to Launch Virtual Platform COVID Advocacy Exchange

May 12, 2020May 13, 2020Shiwani Sharma

Shots: COVID Advocacy Exchange is a virtual platform targeted to unite patient advocacy organizations, patients, policy makers, healthcare practitioners and industry in the [Read More...]

Gilead and Kite Sign a Three Years Agreement with oNKo-innate to Discover Cancer Immunotherapies

April 22, 2020April 22, 2020Tuba Khan

Shots: oNKo-innate to receive an up front, clinical, regulatory & commercial milestones along with royalties on sales of immuno-oncology and cell therapy programs [Read More...]

The US FDA and FTC Sign Agreement to Support the Development of Biosimilars

February 3, 2020March 5, 2020Shiwani Sharma

The partnership will address the false and misleading promotion about biosimilars within their respective authorities and prevent anti-competitive behavior. Additionally, the agencies will [Read More...]

CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights to Facilitate Cell Therapy Programs in Oncology

October 15, 2019October 15, 2019Shiwani Sharma

Shots: CRISPR to gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs [Read More...]

Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer

July 18, 2019July 18, 2019Tuba Khan

Shots: Bayer, BMS and Ono collaborate to evaluate the combination of Bayer’s Stivarga (regorafenib) with BMS & Ono’s Opdivo (nivolumab) vs regorafenib in [Read More...]

Janssen(J&J) Signs an Exclusive Worldwide License Agreement with MeiraGTx for its Gene Therapy Candidates

February 1, 2019June 14, 2019Shiwani Sharma

Shots: Janssen to get exclusive WW license rights to develop & commercialize certain clinical candidates in MeiraGTx’s inherited retinal disease pipeline. Janssen also [Read More...]

Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs)

December 6, 2018June 14, 2019Shiwani Sharma

Shots: Domain to receive upfront, milestones, and royalties on sales from Boehringer Ingelheim The focus of the agreement is to discover & develop [Read More...]